CEO to Speak on Industrial Hemp Opportunities; Medical Marijuana, Inc. PR Firm CMW Media Also Hosting “Children and Cannabis” Panel
SAN DIEGO, April 20, 2017 — Medical Marijuana, Inc. ( MJNA ), the first publicly traded cannabis company in the United States, today announced that its subsidiary HempMeds® is a platinum sponsor of the April 21-22 World Medical Cannabis Conference and Expo in Pittsburgh, Pa., a conference dedicated to the medical science of cannabis.
Medical Marijuana, Inc.’s CEO Dr. Stuart Titus will participate on a panel at the Expo on April 22 at 1:00 p.m. on “Industrial Hemp & the Opportunities Outside of CBD,” discussing the benefits of industrial hemp – a less widely known cash crop that can be used to make thousands of products from nutritional foods, fabrics, ropes, etc. – as an untapped market for massive economic growth in the United States.
“April 17 marks one year since Pennsylvania’s governor signed the state’s medical marijuana program into law, and with the state working to get their medical cannabis program up and running, it’s the perfect time for an educated discussion among medical professionals,” Dr. Titus said. “With Medical Marijuana, Inc. accomplishing the first-ever import approvals for a hemp cannabidiol (CBD) product from the federal governments of Mexico, Brazil and Paraguay, the Company is very excited to share our unique knowledge at the Conference.”
In addition, Medical Marijuana, Inc.’s PR firm CMW Media is hosting a “Children & Cannabis” panel on April 22 at 12:00 p.m., which will include the families of young medical cannabis patients. The panel will consist of the family of Penny Howard, who will speak about how sharing their late daughter Harper’s story to Facebook helped a family in Brazil; medical cannabis activist Raul Elizalde of Mexico, whose family was the first in Mexico to sue the federal government and win the right to import CBD hemp oil to treat their daughter Grace; and Baltimore mother Casandra Stephan along with other families.
HempMeds® representatives will exhibit at booth #205 the Company’s groundbreaking RSHO™ hemp cannabidiol (CBD) oil and zero-THC RSHO-X™, the first-ever cannabis product to receive approval from the federal government of Mexico for importation.
HempMeds® is a corporate portfolio company of Medical Marijuana, Inc. (OTC PINK: MJNA) and the Company’s exclusive master distributor and contracted marketing company, handling sales and distribution.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.
Public Relations Contact:
Chief Executive Officer
P: 888-829- 0070
This article may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.